State Street's passive 5.1% stake is consistent with its role as a large institutional custodian and asset manager. No change in investment strategy is signaled. Monitor for any future 13D conversion, though none is indicated here.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $253.25entry
- T+1 · 6d ago +0.06%α −1.26% · $253.40
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corporation filed a Schedule 13G disclosing beneficial ownership of 7,570,589 shares of Biogen common stock, representing 5.1% of shares outstanding as of September 30, 2026. This is a passive investment filing with no activist intent, and State Street has held a 5%+ stake in prior periods as well.
Key Financial Metrics
Key Facts
- State Street Corporation reported beneficial ownership of 7,570,589 shares of Biogen common stock as of September 30, 2026.
- The stake represents 5.1% of Biogen's outstanding shares.
- State Street certifies the shares were acquired and held in the ordinary course of business, not to change or influence control.
- The filing is an initial Schedule 13G by State Street for this position; prior filings by Fidelity (a different filer) show a separate 5%+ stake.
Financial Impact
State Street holds 7,570,589 shares, approximately 5.1% of Biogen's outstanding shares. At a market cap of $36.7B, the stake is valued at roughly $1.87B.
Risk Factors
- No material risks identified from this passive filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000623 |
| Document: 0000093751-26-000623-index.html | 0000093751-26-000623 |
| Document: 0000093751-26-000623.txt | 0000093751-26-000623 |
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers